Targepeutics Presenting Data at 29th Annual Meeting of the Society of Neuro-Oncology (SNO)

Targepeutics is presenting the latest preclinical data related to ongoing development of the novel immunotoxin, GB13, for the treatment of GBM.  This data will presented as a poster presentation during the 29th Annual Meeting for the Society of Neuro-Oncology, being held in Houston, TX from November 21-24th.

Dr Randy Schrecengost, Chief Scientific Officer, will present the poster entitled “GB13 is a Potent Neoadjuvant Treatment Option for IL13R⍺2-expressing GBM and Improves Standard-of-Care Therapy” during the Friday evening poster session. Key highlights from the data demonstrate that GB13 pretreatment prior to radiation treatment is able to increase cell death, which is similar to results observed in pediatric diffuse midline glioma. The findings are also dependent on IL13R⍺2 expression. The presentation further supports the clinical strategy to combine GB13 with standard-of-care radiation.

Details for the presentation:

Title: GB13 is a Potent Neoadjuvant Treatment Option for IL13R⍺2-expressing GBM and Improves Standard-of-Care Therapy

Presenter: Randy Schrecengost, PhD, Targepeutics Chief Scientific Officer of Targepeutics

Abstract number: DNAR-09

Date and Time: Friday , November 22, 2024 from 7:30 – 9:30 PM CT

Location: Hall B3, George R Brown Convention Center